Shanghai Haohai Biological Technology Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Shanghai Haohai Biological Technology hat ein Gesamteigenkapital von CN¥6.0B und eine Gesamtverschuldung von CN¥423.7M, wodurch sich der Verschuldungsgrad auf 7% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CN¥7.2B bzw. CN¥1.2B. Shanghai Haohai Biological Technology Das EBIT des Unternehmens beträgt CN¥404.8M, so dass der Zinsdeckungsgrad -6.4 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CN¥2.7B.

Wichtige Informationen

7.0%

Verhältnis von Schulden zu Eigenkapital

CN¥423.70m

Verschuldung

Zinsdeckungsgrad	-6.4x
Bargeld	CN¥2.69b
Eigenkapital	CN¥6.03b
Gesamtverbindlichkeiten	CN¥1.21b
Gesamtvermögen	CN¥7.25b

Jüngste Berichte zur Finanzlage

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Jul 25

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Apr 17

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Nov 14

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 28

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Mar 09

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Nov 25

Recent updates

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Jul 25

Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

May 22

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Apr 17

Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Feb 12

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Nov 14

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 28

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Mar 09

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Nov 25

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 30

Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

May 08

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Apr 19

Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Mar 04

Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Mar 03

Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Jan 10

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Oct 08

Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Jul 07

Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

May 27

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Apr 04

Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%

Mar 16

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 6826Die kurzfristigen Aktiva des Unternehmens (CN¥3.7B) übersteigen seine kurzfristigen Passiva (CN¥861.5M).

Langfristige Verbindlichkeiten: 6826Die kurzfristigen Vermögenswerte des Unternehmens (CN¥3.7B) übersteigen seine langfristigen Verbindlichkeiten (CN¥350.6M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 6826 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 6826Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0.7% auf 7% gestiegen.

Schuldendeckung: 6826Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (159%).

Zinsdeckung: 6826 mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.

Shanghai Haohai Biological Technology Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Recent updates

Third quarter 2024 earnings released: EPS: CN¥2.19 (vs CN¥0.36 in 3Q 2023)

Investor sentiment deteriorates as stock falls 21%

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 20%

Shanghai Haohai Biological Technology Co., Ltd. Approves Interim Dividend for the Six Months Ended 30 June 2024

Upcoming dividend of CN¥0.40 per share

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback for 2,229,405 shares, representing 0.95% for CNY 200 million.

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

New minor risk - Dividend sustainability

Shanghai Haohai Biological Technology Co., Ltd. Announces to Distribute A Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of CN¥1.00 per share

Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

First quarter 2024 earnings released: EPS: CN¥0.58 (vs CN¥0.60 in 1Q 2023)

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, May 29, 2024

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released

Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Now 28% overvalued

Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023

Shanghai Haohai Biological Technology Co., Ltd. Announces Resignation of Guo Yongqing as Independent Non-Executive Director, Chairman of Audit Committee, Member of Remuneration and Appraisal Committee and Member of Nomination Committee

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Third quarter 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.32 in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023

Investor sentiment improves as stock rises 15%

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback.

Second quarter 2023 earnings released: EPS: CN¥0.73 (vs CN¥0.059 in 2Q 2022)

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Shanghai Haohai Biological Technology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Upcoming dividend of HK$0.44 per share at 1.4% yield

Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on August 11, 2023

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 12, 2023

First quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.35 in 1Q 2022)

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Full year 2022 earnings released: EPS: CN¥1.04 (vs CN¥2.00 in FY 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Less than half of directors are independent

Third quarter 2022 earnings released

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.76 in 2Q 2021)

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2022 Results on Aug 26, 2022

Shanghai Haohai Biological Technology Co., Ltd. Provides Financial Guidance for the Six Months Ended 30 June 2022

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.82 per share

Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2021

Investor sentiment improved over the past week

Shanghai Haohai Biological Technology Co., Ltd. Announces Retirement of Li Yingqi as Independent Non-Executive Director

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 29, 2022

Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2022 Results on Apr 29, 2022

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Full year 2021 earnings: Revenues miss analyst expectations

Shanghai Haohai Biological Technology Co., Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Consensus revenue estimates fall by 11%

Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2021 earnings: Revenues miss analyst expectations

Shanghai Haohai Biological Technology Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2021